Art. -Nr.: HY-Y0106

2,6-Dihydroxyacetophenone

Kundenbewertung

Based on 1 Customer Validation

2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 699-83-2
Formel: C₈H₈O₃
Molecular Weight:152.15

Speicherung:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

2,6-Dihydroxyacetophenone Chemical Structure

CAS. Nr.: 699-83-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle mTOR Isoform-spezifische Produkte anzeigen :

In Vitro

2,6-Dihydroxyacetophenone (5-40 µM, 48 h) inhibits cell growth and proliferation of HCT8 cells^[1].
2,6-Dihydroxyacetophenone (10-100 µM, 24-48 h) arrests the cell cycle at the G0/G1 phase, induces apoptosis and suppresses cell migration in HCT8 cells^[1].
2,6-Dihydroxyacetophenone (40 µM, 48 h) reduces the expression of p70S6K1 and AKT1 in HCT8 cells^[1].
2,6-Dihydroxyacetophenone (0.1-2 mM) inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM^[2].
2,6-Dihydroxyacetophenone (200 µM, 48 h) decreases the survival rate of BRL 3A cells^[2].
2,6-Dihydroxyacetophenone (0.325-1.3 mM, 24 h) inhibits lipid accumulation in FFA-induced LO2 cells, and 1.3 mM reduces intracellular TG levels^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HCT8 cells
Concentration:

5, 10, 20, 40 μM
Incubation Time:

48 h
Result:

Inhibited cell growth and proliferation of HCT8 cells.

Cell Cycle Analysis^[1]

Cell Line:

HCT8 cells
Concentration:

40 μM
Incubation Time:

24 h
Result:

Arrested HCT8 cells in G0/G1 phase of cell cycle with a 10% reduction in the percentage in the G2/M phase.

Apoptosis Analysis^[1]

Cell Line:

HCT8 cells
Concentration:

40, 80, 100 μM
Incubation Time:

48 h
Result:

Reduced the BCL2 expression.
Induced the BID expression.
Reduced the expression of p70S6K1 and AKT1.

Cell Migration Assay ^[1]

Cell Line:

HCT8 cells
Concentration:

10, 20, 40 μM
Incubation Time:

48 h
Result:

Suppressed colorectal cancer cell migration.

In Vivo

2,6-dihydroxyacetophenone (40 mM/kg, i.g., daily, 21 days) improves uric acid metabolism disorder in hyperuricemia mice^[4].
2,6-dihydroxyacetophenone (60.86 mg/kg (400 μmol/kg), i.g., twice daily, 3 weeks) decreases plasma cholesterol levels in hypercholesterolemic rats^[5].
2,6-dihydroxyacetophenone (7 mg/kg, i.g., daily, 8 weeks) inhibits lipid accumulation high-fat diet (HFD)-induced obese mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

A hyperuricemia (HUA) mouse model (8-week male Kunming mice), which was established by daily intragastric administration of Hypoxanthine (HY-N0091) (500 mg/kg), intraperitoneal injection of Potassium oxonate (HY-17511) (300 mg/kg), and supplementation with 10% fructose water^[4].
Dosage:

40 mM/kg
Administration:

i.g. daily for 21 days
Result:

Reduced serum UA levels in HUA mice.
Inhibited XOD activity in serum and liver.
Decreased serum CRE and BUN levels.
Improved renal tissue inflammatory infiltration and renal tubular lesions.
Increased the relative abundance of Lactobacillus.
Reduced the proportion of Firmicutes, and the abundance of Proteobacteria and Actinobacteria.
Regulated the gut microbiota structure.
Had no significant effect on the body weight and liver and kidney coefficients of mice.

Animal Model:

Adult male Sprague-Dawley rats (weighing 200-250g) were fed a high-cholesterol diet containing 1.5% cholesterol and 0.5% cholic acid for 3 weeks to induce hypercholesterolemia^[5].
Dosage:

60.86 mg/kg (400 μmol/kg)
Administration:

i.g. twice daily for 3 weeks
Result:

Decreased Plasma cholesterol levels in hypercholesterolemic rats significantly after 2 weeks treatment, and this effect persisted until the 3rd week.
Decreased the plasma cholesterol to 152 mg/dl.

Animal Model:

Male and female KM mice (4 weeks) received high-fat diet (DIO series diets, 60% H10060)^[6].
Dosage:

7 mg/kg
Administration:

i.g. daily for 8 weeks
Result:

Caused a decreasing trend in body weight gain of mice compared with the HFD group.
Reduced the serum levels of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) in mice.
Decreased the atherosclerosis index (AI) and coronary artery risk index (CRI) of mice.
Reversed the HFD-induced gut microbiota dysbiosis in mice.
Increased the relative abundance of the genus Odoribacter in the gut of mice.
Decreased the abundances of the genera Helicobacter and Mucispirillum in the gut of mice.
Reduced the HFD-induced increase in the Firmicutes/Bacteroidetes ratio in the gut of mice.

Chemical Information

CAS. Nr. 699-83-2
Appearance Solid
Molecular Weight 152.15
Formel C₈H₈O₃
Color Light yellow to yellow
SMILES

CC(C1=C(O)C=CC=C1O)=O
Structure Classification
- Phenols
- Polyphenols
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (657.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.5725 mL

32.8623 mL

65.7246 mL

5 mM

1.3145 mL

6.5725 mL

13.1449 mL

10 mM

0.6572 mL

3.2862 mL

6.5725 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Awasthi A, et al. Invitro Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in Colorectal Cancer Therapy. Pathol Oncol Res. 2019 Jan;25(1):301-309. [Content Brief]

[2]. Liu X, et al. Characterization of xanthine oxidase inhibitory activities of phenols from pickled radish with molecular simulation. Food Chem X. 2022 May 21;14:100343. [Content Brief]

[3]. Rezk BM, et al. The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochem Biophys Res Commun. 2002 Jul 5;295(1):9-13. [Content Brief]

[4]. Xiaoze Liu, et al.Three dietary phenols from pickled radish improve uric acid metabolism disorder in hyperuricemia mice associated with the altered gut microbiota composition.

[5]. Kanchanapoo J, et al. Inhibitory effects of choleretic hydroxyacetophenones on ileal bile acid transport in rats. Life Sci. 2006 Feb 28;78(14):1630-6. [Content Brief]

[6]. Li J, et al. Three Novel Dietary Phenolic Compounds from Pickled Raphanus Sativus L. Inhibit Lipid Accumulation in Obese Mice by Modulating the Gut Microbiota Composition. Mol Nutr Food Res. 2021 Mar;65(6):e2000780. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.5725 mL	32.8623 mL	65.7246 mL	164.3115 mL
	5 mM	1.3145 mL	6.5725 mL	13.1449 mL	32.8623 mL
	10 mM	0.6572 mL	3.2862 mL	6.5725 mL	16.4312 mL
	15 mM	0.4382 mL	2.1908 mL	4.3816 mL	10.9541 mL
	20 mM	0.3286 mL	1.6431 mL	3.2862 mL	8.2156 mL
	25 mM	0.2629 mL	1.3145 mL	2.6290 mL	6.5725 mL
	30 mM	0.2191 mL	1.0954 mL	2.1908 mL	5.4771 mL
	40 mM	0.1643 mL	0.8216 mL	1.6431 mL	4.1078 mL
	50 mM	0.1314 mL	0.6572 mL	1.3145 mL	3.2862 mL
	60 mM	0.1095 mL	0.5477 mL	1.0954 mL	2.7385 mL
	80 mM	0.0822 mL	0.4108 mL	0.8216 mL	2.0539 mL
	100 mM	0.0657 mL	0.3286 mL	0.6572 mL	1.6431 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

2,6-Dihydroxyacetophenone

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Phenols Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Chinese Baijiu Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

2,6-Dihydroxyacetophenone Related Classifications

HY-Y0106 Related Classifications